Raju Mohan: Yes, I’ll deal with the second question and I’ll have Bill address the first one. So as we guided in the last earnings call, we’ve initiated all necessary activities around Phase 3 prep for both programs. So this includes CMC work, drug substance, drug product, regulatory preparation for end of Phase 2 meetings, all of the clinical studies that are needed to support that certain domain PK study. So all that has been well planned and it’s on track. Again, we’re planning for data release in the fourth quarter, and then moving on seamlessly to Phase 3 start. So yes, all necessary activities. There will be no delay due to anything that’s not planned or executed both on the CMC side, the reg side, the clinical side, and all the other planning that goes to these trials. So, Bill, why don’t you address the first question?
Bill Sandborn: Sure. So what is the utility of the different PASI outcome measures for Phase 2 dose finding? We have both Phase 2 data fully published with Sotyktu in abstract form with the Takeda-Nimbus product. But we also have Phase 2 trial data with a number of the anti-IL-23 antibodies. And what you see across both the TYK2 inhibitors and the antibodies is that, first of all, we know that psoriasis is exquisitely sensitive to IL-23 inhibition. So you see relatively high levels of — respectively, if PASI 75, 90 and 100 as you go up on dosing. But I would say the most sensitive outcome measure seems to be PASI 75. And you will sometimes see sort of a blending of several dose groups across the range of three or four doses for PASI 75.
And then as you go up to PASI 90 and especially PASI 100, that seems to be more specific or differentiating. So the absolute rates of achieving PASI 100 in particular will be lower often, half or less of what it is with PASI 75. And that tends to separate groups better. And that was seen both with Sotyktu with the 12 milligram once a day dose in Phase 2 and with the Nimbus-Takeda product at the 30 milligram dose that each of the highest doses and highest exposures had the greatest achievement of PASI 100. So that’s sort of how we see it.
Unidentified Analyst: Very helpful. Thank you so much.
Operator: Thank you. Our next question will come from Derek Archila with Wells Fargo.
Derek Archila: Hi, guys. Thanks for taking the questions and congrats on the progress here. Just two quick ones from us. I guess first, can you just remind us how we should be thinking about the geographical diversity from the Phase 2 trial with VTX002 in terms of like number of U.S. sites versus ex-U.S. sites? And then maybe I missed this in the prepared remarks. But I guess when are we going to see the data for VTX2735? And how are you thinking about prioritizing either indications or potentially partnering that asset in the future? Thanks.
Raju Mohan: Bill, why don’t you take both of them and then maybe I can add to the future of 2735? But why don’t you begin.
Bill Sandborn: Yes. So for geographic diversity, inflammatory bowel disease trials, whether it’s ulcerative colitis in the case of VTX002 or Crohn’s disease in the case of VTX958, you really require a lot of clinical trial sites as you get into Phase 2 and you’re requiring anywhere from 132 patients target enrollment for Crohn’s disease or 180 patients target enrollment for the now enrolled ulcerative colitis trial. So those end up being multiple countries and worldwide development programs. It’s typical to have greater enrollment in Eastern Europe, but to have enrollment in Western Europe and North America as well. We are in all of those jurisdictions in the ulcerative colitis trial. I think we won’t get into details about exactly the distribution of the trial sites except to say it’s pretty conventional for a Phase 2 trial and I feel very comfortable with the geographic mix that we achieved, and we’ll report that when we report the data in the fourth quarter.
